华纳药厂：盐酸异丙肾上腺素注射液获药品注册证书

Core Viewpoint - Warner Pharmaceuticals (688799) has received approval from the National Medical Products Administration for the registration certificate of Isoproterenol Hydrochloride Injection, which is used for treating cardiogenic or infectious shock, complete atrioventricular block, and cardiac arrest [1] Group 1 - The approval of Isoproterenol Hydrochloride Injection marks a significant milestone for the company in expanding its product offerings in critical care [1] - The drug is indicated for serious medical conditions, potentially increasing its market demand and relevance in emergency medicine [1] - This development may enhance the company's competitive position within the pharmaceutical industry, particularly in the cardiovascular treatment segment [1]